Assessing AptarGroup (ATR) Valuation After First Quarter Earnings Beat And Profit softness

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

AptarGroup (ATR) has drawn fresh attention after reporting first quarter 2026 results that topped consensus forecasts for both earnings and revenue, even though net income and earnings per share were lower than a year earlier.

See our latest analysis for AptarGroup.

Even with the earnings and revenue beat, AptarGroup’s recent share price performance has been weak, with a 30 day share price return decline of 6.1% and a 1 year total shareholder return decline of 20.9%, pointing to fading momentum despite the new product launches and dividend affirmation.

If this earnings reaction has you reassessing packaging and materials names, it could be a good moment to broaden your search through 18 top founder-led companies

With AptarGroup trading below some estimated intrinsic value measures after an earnings beat but softer profit figures, the key question is whether recent share weakness signals an undervalued compounder or whether the market is already discounting future growth.

Most Popular Narrative: 26.3% Undervalued

AptarGroup's most followed narrative sets a fair value of $161.43 against a last close of $119.02, framing the recent share pullback as a discount to its long term cash generation potential under that view.

The rapid expansion of AptarGroup's proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Read the complete narrative.

Want to see what kind of revenue mix, earnings path, and future P/E multiple underpin that valuation gap, and how buybacks and margins fit into the story.

Result: Fair Value of $161.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on legal costs from intellectual property disputes and uncertain demand for emergency medicine delivery systems not eroding the margin and earnings profile that support this thesis.

Find out about the key risks to this AptarGroup narrative.

Another View: Market Pricing Looks Less Generous

The DCF work suggests AptarGroup is trading about 33.4% below an estimated future cash flow value of $178.59, yet the simpler earnings multiple tells a different story. At a P/E of 19.6x versus a fair ratio of 18.5x, the shares screen as expensive, with a richer P/E than both US and global packaging peers. For investors, that mix of DCF upside and premium earnings pricing raises a clear question: which signal deserves more weight?

Story Continues

See what the numbers say about this price — find out in our valuation breakdown.NYSE:ATR P/E Ratio as at May 2026

Next Steps

Seeing mixed signals on value, growth, and sentiment around AptarGroup, it makes sense to check the underlying data yourself and not rely on a single narrative. You can take a closer look at the company's 5 key rewards and 2 important warning signs

Looking for more investment ideas?

If AptarGroup has sharpened your focus on quality but you do not want to stop at one name, now is the time to widen your net using targeted stock lists designed around clear fundamentals and risk profiles.

Target potential value opportunities by scanning 51 high quality undervalued stocks that combine strong cash generation with prices that sit below many estimate based fair value ranges. Prioritise resilience by reviewing 67 resilient stocks with low risk scores so you can focus on companies with lower risk scores instead of spreading capital across names you know little about. Get ahead of the crowd by searching screener containing 25 high quality undiscovered gems where solid fundamentals have not yet attracted wide market attention, so you are not always arriving late to the idea.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ATR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments